NcXHF

MANAGEMENT OF DLBCL BASED ON MOLECULAR PROFILE
B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin,
vincristine, and prednisone. J Clin Oncol. 2012;30:3460-3467.
52. Hu S, Xu-Monette ZY, Tzankov A, et al. MYC/BCL2 protein coexpression
contributes to the inferior survival of activated B-cell subtype of
diffuse large B-cell lymphoma and demonstrates high-risk gene expression
signatures: a report from The International DLBCL Rituximab-
CHOP Consortium Program. Blood. 2013;121:4021-4031;4250.
53. Johnson NA, Slack GW, Savage KJ, et al. Concurrent expression of MYC
and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus
cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin
Oncol. 2012;30:3452-3459.
54. Perry AM, Alvarado-Bernal Y, Laurini JA, et al. MYC and BCL2 protein
expression predicts survival in patients with diffuse large B-cell lymphoma
treated with rituximab. Br J Haematol. 2014;165:382-391.
55. Cheah CY, Oki Y, Westin JR, et al. A clinician’s guide to double hit lymphomas.
Br J Haematol. Epub 2014 Dec 22.
56. Lindsley RC, LaCasce AS. Biology of double-hit B-cell lymphomas. Curr
Opin Hematol. 2012;19:299-304.
57. Howlett C, Landsburg DJ, Chang EA, et al. Front-line, dose-escalated
immunochemotherapy is associated with a signifıcant PFS (but not
OS) advantage in 401 patients (pts) with double-hit lymphomas
(DHL): A SYSTEMIC REVIEW AND META-ANALYSis. Blood. 2014;
124: (suppl; abstr 3056).
58. Dunleavy K, Fanale M, LaCasce AS, et al. Preliminary report of a multicenter
prospective phase II study of DA-EPOCH-R in MYC-rearranged
aggressive B-cell lymphoma. Blood. 2014;124: (suppl; abstr 395).
59. Greenwood M, Amytage T, Fay K, et al. Outcomes of allogeneic stem
cell transplantation for non-Hodgkin lymphoma with concurrent MYC
and BCL2 translocations: a single centre retrospective analysis. Hematol
Oncol. 2013;31:96-150.
60. Oki Y, Noorani M, Lin P, et al. Double hit lymphoma: the MD Anderson
Cancer Center clinical experience. Br J Haematol. 2014;166:891-901.
61. Johnson NA, Savage KJ, Ludkovski O, et al. Lymphomas with concurrent
BCL2 and MYC translocations: the critical factors associated with
survival. Blood. 2009;114:2273-2279.
62. Li S, Lin P, Fayad LE, et al. B-cell lymphomas with MYC/8q24 rearrangements
and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease
with heterogeneous histology, germinal center B-cell immunophenotype
and poor outcome. Mod Pathol. 2012;25:145-156.
63. Davids MD, Seymour JF, Gerecitano JF, et al. Phase I study of ABT-199
(GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin
lymphoma (NHL): responses observed in diffuse large B-cell (DLBCL)
and follicular lymphoma (FL) at higher cohort doses. J Clin Oncol. 2014;
32: (suppl, abstr 8522).
64. Thieblemont C, Stathis A, Inghirami G, et al. A Phase I study of the
BET-Bromodomain inhibitor OTX015 in patients with non-Leukemic
hematologic malignancies. Blood. 2014;124: (suppl, abstr 4417).
65. Trabucco SE, Gerstein RM, Evens AM, et al. Inhibition of bromodomain
proteins for the treatment of human diffuse large B-cell lymphoma.
Clin Cancer Res. 2015;21:113-122.
66. Mirguet O, Lamotte Y, Donche F, et al. From ApoA1 upregulation to
BET family bromodomain inhibition: Discovery of I-BET151. Bioorg
Med Chem Lett. 2012;22:2963-2967.
67. Kochenderfer JN, Dudley ME, Kassim SH, et al. Chemotherapyrefractory
diffuse large B-cell lymphoma and indolent B-cell malignancies
can be effectively treated with autologous T cells expressing an anti-
CD19 chimeric antigen receptor. J Clin Oncol. 2015;33:540-549.
68. Sauter CS, Riviere I, Bernal YJ, et al. Interim safety analysis: a phase I
trial of high dose therapy and autologous stem cell transplantation followed
by infusion of chimeric antigen receptor modifıed T-cells (19-28z
CAR-T) directed against CD19 B-cells for relapsed and refractory aggressive
B-cell non-Hodgkin lymphoma (B-NHL). Blood. 2014;124:
(suppl, abstr 677).
69. den Hollander J, Rimpi S, Doherty JR, et al. Aurora kinases A and B are
up-regulated by Myc and are essential for maintenance of the malignant
state. Blood. 2010;116:1498-1505.
70. Mahadevan D, Morales C, Cooke LS, et al. Alisertib added to rituximab
and vincristine is synthetic lethal and potentially curative in mice with
aggressive DLBCL co-overexpressing MYC and BCL2. PLoS One. 2014;
9:e95184.
71. Pourdehnad M, Truitt ML, Siddiqi IN, et al. Myc and mTOR converge
on a common node in protein synthesis control that confers synthetic
lethality in Myc-driven cancers. Proc Natl Acad Sci USA.2013;110:
11988-11993.
72. Smith SM, van Besien K, Karrison T, et al. Temsirolimus has activity in
non-mantle cell non-Hodgkin’s lymphoma subtypes: the University of
Chicago phase II consortium. J Clin Oncol. 2010;28:4740-4746.
73. Evens AM, Dashnamoothy R, Kandela I, et al. The novel 2nd generation
proteasome inhibitor MLN99708 induces redox- and MAPK-related
cell death in T-cell lymphoma (TCL) and Hodgkin lymphoma (HL) cell
lines and human lymphoma xenograft models. Hematol Oncol. 2013;
31:30.
74. Gopal AK, Kahl BS, de Vos S, et al. PI3Kdelta inhibition by idelalisib in
patients with relapsed indolent lymphoma. N Engl J Med. 2014;370:
1008-1018.
75. Sheth A, Escobar-Alvarez S, Gardner J, et al. Inhibition of human
mitochondrial peptide deformylase causes apoptosis in c-mycoverexpressing
hematopoietic cancers. Cell Death Dis. 2014;5:e1152.
76. Jeong SM, Lee A, Lee J, et al. SIRT4 protein suppresses tumor formation
in genetic models of Myc-induced B cell lymphoma. J Biol Chem. 2014;
289:4135-4144.
asco.org/edbook | 2015 ASCO EDUCATIONAL BOOK
e457